

Comparison of Three Aqueous Aerosol Inhalation Devices for Delivering Anti-tuberculosis Bacteriophage D29



Nicholas B. Carrigy,¹ Rachel Y. Chang,² Sharon S.Y. Leung,² Melissa Harrison,³ Zaritza Petrova,⁴ Welkin H. Pope,⁴ Graham F. Hatfull,⁴ Warwick J. Britton,⁵ Hak-Kim Chan,² Dominic Sauvageau,³ Warren H. Finlay,¹ and Reinhard Vehring¹

1. Department of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada; 2. Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia; 3. Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, Canada; 4. Department of Biological Sciences, University of Pittsburgh, PA, USA; 5. Centenary Institute of Cancer and Cell Biology, and Sydney Medical School, Royal Prince Alfred Hospital, and University of Sydney, Sydney, NSW, Australia

Introduction

- ↑ Antibiotic-resistance
- ✓ Phage therapy is an alternative [1,2]
- # Need many phage in lungs relative to bacteria [3]
- ! Inhalation device must not deactivate the phage

Materials and Methods




Figure 1: Morphological components of a tailed phage [4], and TEM of phage D29, which lyses *M. tuberculosis*.




Figure 2: Lytic cycle [5], and *M. smegmatis* plaque assay plate.



Figure 3: Tested inhalation devices & collection filter [6-9].

Results and Discussion

Table 1: Phage D29 deactivation due to aerosolization and rate active phage exit the respective devices.

Inhalation Device	Deactivation (%) *	Active Phage Delivery Rate
Jet Nebulizer	99.981 ± 0.005	7.1x10 ⁴ ± 1.7x10 ⁴ pfu/min
Vibrating Mesh Nebulizer	60 ± 11	3.3x10 ⁸ ± 0.8x10 ⁸ pfu/min
Soft Mist Inhaler	72 ± 14	4.6x10 ⁶ ± 2.0x10 ⁶ pfu/dose

* < 90% deactivation is acceptable




Figure 4: Mathematical prediction for phage nebulization cycle count with the jet nebulizer.




Figure 5: Droplet production with the jet nebulizer.

Vibrating Mesh Nebulizer
Relatively unharmed to D29
Delivers active phage D29 ~5000 times faster than the jet nebulizer




Figure 6: Vibrating mesh nebulizer droplet production mechanism: (a) the structure surrounding the aperture plate, (b) close-up of a funnel-shaped orifice in the aperture plate illustrating the micropump action, which ejects droplets.

Soft Mist Inhaler
Relatively unharmed to D29
A single 11.6 ± 1.6 μL dose delivers as much active phage as 1 hour of delivery with the jet nebulizer




Figure 7: Schematic of the soft mist inhaler. The shear and pressurization was relatively unharmed to D29.

Conclusions

- Ensure your inhalation device does not deactivate the phage before starting pulmonary experiments
- Titer reduction is inhalation device- and phage strain-dependent
- Jet nebulization can deactivate D29; deactivation is likely due to stresses during baffle impaction and renebulization
- Other phage readily survive jet nebulization [10]
- Vibrating mesh nebulizer is a good choice for starting animal studies with D29
- Soft mist inhaler may be useful for self-administration, being pocket-sized and multidose
- Phage therapy using inhalation devices is feasible, and promising

References

1. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM: Phage treatment of human infections. *Bacteriophage* 2011, 1: 66-85.
2. Kutateladze M, Adamia R: Bacteriophages as potential new therapeutics to replace or supplement antibiotics. *Trends Biotechnol* 2010, 28: 591-95.
3. Semler DD, Goudie AD, Finlay WH, Dennis JJ: Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. *Antimicrob Agents Chemother* 2014, 58: 4005-13.
4. Image from: <https://en.wikipedia.org/wiki/Bacteriophage>
5. Sabehi G, Shaulov L, Silver DH, Yanai I, Harel A, Lindell D: A novel lineage of myoviruses infecting cyanobacteria is widespread in the oceans. *PNAS* 2012, 109: 2037-42.
6. Image from: <https://www.inspiration-medical.de/Bilder/Aerogen%20Solo%20Vernebler%20ex%20Aeroneb.jpg>
7. Image from: <https://online.ebos.co.nz/images/product/22143069%20-%20BOY%20SX.jpg>
8. Image from: http://d3hjf51r9j54j7.cloudfront.net/wp-content/uploads/sites/5/2008/01/spiriva_respimatw_image1_3.jpg
9. Image from: <http://www.wms.co.uk/sharedimages/Zoom/D630.jpg>
10. Golshahi L, Seed KD, Dennis JJ, Finlay WH: Toward modern inhalation bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. *J Aerosol Med Pulm Drug Deliv*. 2008, 21: 351-60.

Acknowledgements

The authors thank Arlene Oatway for help with the transmission electron micrograph and Jim Fink for providing Aerogen nebulizers and equipment.

